Who are Ketamine + magnesium's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, Intravenous anesthetic, Magnesium sulfate administration.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketamine-magnesium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ketamine + magnesium — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ketamine + magnesium (Ketamine + magnesium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist combination. Area: Psychiatry, Pain Management.

marketed NMDA receptor antagonist combination NMDA receptor Psychiatry, Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ketamine + magnesium (Ketamine + magnesium) — University of Chile. Ketamine blocks NMDA receptors while magnesium enhances this blockade and stabilizes the drug's effects, together producing rapid-onset antidepressant and analgesic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketamine + magnesium TARGET	Ketamine + magnesium	University of Chile	marketed	NMDA receptor antagonist combination	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Intravenous anesthetic	Intravenous anesthetic	University of Pennsylvania	marketed	GABA-A receptor agonist / NMDA receptor antagonist (class-dependent)	GABA-A receptor or NMDA receptor (varies by specific agent)
Magnesium sulfate administration	Magnesium sulfate administration	University of California, San Francisco	marketed	Electrolyte/mineral supplement; anticonvulsant	NMDA receptor; L-type calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist combination class)

Ain Shams University · 1 drug in this class
National Cancer Institute, Egypt · 1 drug in this class
National Cheng-Kung University Hospital · 1 drug in this class
University of Chile · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketamine + magnesium — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamine-magnesium. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing